For example, Romero et al. have shown that SMARCA4-deficient lung cancer cells do not respond to HDAC inhibition but in contrast are sensitive to inhibition of the demethylases KDM6A/B, even if MYC is concurrently amplified [56]. Here, MBD2 is linked to lung carcinoma.